BD announced on Wednesday that Chief Financial Officer Chris DelOrefice will be departing the company on December 5 to explore a new professional opportunity. The company is currently in the process of identifying a permanent successor. DelOrefice, who has accepted a position as CFO at Ulta Beauty, communicated his intention to resign on October 9, as noted in a regulatory filing. He joined BD in 2021 after nearly two decades at Johnson & Johnson.
In the interim, Vitor Roque, who serves as senior vice president of finance, business units, and corporate financial planning and analysis, will step in as BD’s interim CFO following DelOrefice’s departure. Roque will collaborate closely with DelOrefice and BD’s leadership teams to ensure a smooth transition. With two decades of experience at BD and a history of supporting key acquisitions, Roque is well-positioned for this role. CEO Tom Polen expressed confidence in Roque’s capabilities, stating, “His strong finance and leadership capabilities position him well to serve as interim CFO as we continue to deliver on our strategic goals.”
BD clarified that DelOrefice’s decision to leave is not related to any disagreements regarding financial statements, reporting, operations, policies, or practices.
Fourth-quarter results
In addition to the leadership changes, BD revealed preliminary fiscal fourth-quarter revenue of approximately .9 billion, reflecting an 8.3% increase year over year. For the fiscal year 2025, the company reported preliminary revenue of about .8 billion, marking an 8.2% rise.
However, analysts at Stifel described the fourth-quarter results as “disappointing,” falling short of consensus expectations. Polen acknowledged that the “dynamic macro environment” had a more significant impact than anticipated during the quarter, particularly affecting the vaccines and academic and government research sectors. Conversely, growth remained robust in BD’s interventional, patient monitoring, and medication delivery divisions.
Looking ahead, BD is planning to separate its biosciences and diagnostics business from the rest of the company. In July, it was announced that Waters and the BD business would merge in a deal valued at approximately .5 billion. BD is set to discuss its fiscal fourth-quarter and full-year earnings during an earnings call scheduled for November 6.
